Adjuvant Bevacizumab Does Not Improve Survival in NSCLCAdjuvant Bevacizumab Does Not Improve Survival in NSCLC

The addition of bevacizumab to standard chemo regimens does not improve overall or disease-free survival in patients with resected non-small cell lung cancer (NSCLC). Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

AbstractPurposeBased on an exceptionally durable response to pemetrexed observed in some patients with metastatic NSCLC, the predictive value of pemetrexed sensitivity to outcomes of subsequent systemic treatment was investigated.MethodsWe retrospectively reviewed the patients with metastatic non-squamous NSCLC treated with pemetrexed monotherapy as their first- or second-line chemotherapy between November 2006 and February 2015. Good (top 5% longest) and poor responders (bottom 12% shortest) were defined according to the duration of pemetrexed maintenance. The first and second post-pemetrexed (PP) systemic treatments were...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
This study demonstrates that NSCLC cells resistant to gefitinib (GR cells) displayed a significantly higher microsomal prostaglandin E synthase-1 (mPGES-1) expression and activity than parental cells. Overexpression of mPGES-1/prostaglandin E-2 (PGE-2) signaling in GR cells was associated with acquisition of mesenchymal and stem-like cell properties, nuclear EGFR translocation and tolerance to cisplatin. mPGES-1 inhibition reduced mesenchymal and stem-like properties, and nuclear EGFR translocation in GR cells. Consistently, inhibition of mPGES-1 activity enhanced sensitivity to cisplatin and responsiveness to gefitinib in...
Source: Prostaglandins and Other Lipid Mediators - Category: Lipidology Source Type: research
This study aimed to clarify whether CT-histogram analysis of tumors can be used to classify patients with clinical stage 0-IA non-small cell lung cancer (c0-IA NSCLC) according to pathological lymph node (pN) status.MethodsPredictive factors associated with pN metastasis (pNM) were identified from the derivation dataset including 629 patients with c0-IA NSCLC who underwent complete resection with lymph node dissection (surgeries between 2008 and 2013). The validation dataset including 238 patients (surgeries between 2014 and 2015) were subsequently re-evaluated. Clinico-surgical factors, including CT-histogram parameters o...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
A Prediction Rule for Overall Survival in Non-Small-Cell Lung Cancer Patients with a Pathological Tumor Size Less Than 30 mm. Dis Markers. 2019;2019:8435893 Authors: Zhu WY, Fang KX, He JY, Cui R, Zhang YK, Le HB Abstract We sought to develop and validate a clinical nomogram model for predicting overall survival (OS) in non-small-cell lung cancer (NSCLC) patients with resected tumors that were 30 mm or smaller, using clinical data and molecular marker findings. We retrospectively analyzed 786 NSCLC patients with a pathological tumor size less than 30 mm who underwent surgery betwee...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
The role of adjuvant therapy in resected non-small cell lung cancer has been a contentious issue for decades. The current standard of adjuvant chemotherapy1 was only proven by the completion of a series of modern international trials when a first set of older trials failed to demonstrate significant benefit.2 The Lung Adjuvant Cisplatin Evaluation meta-analysis of modern trials demonstrated a significant overall survival improvement of ∼5%.3 This does not seem to extend to molecular targeted therapies for resected Epidermal Growth Factor Receptor or ALK+ non-small cell lung cancer because improvement is seen only ...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
There has been no recent randomized evidence justifying postoperative radiation therapy (PORT) in patients with non-small cell lung cancer who have undergone complete resection; it is not recommended for routine use, even in patients with mediastinal involvement (pN2).1,2 Adjuvant treatments such as chemotherapy and PORT should be discussed at a multidisciplinary board with complete surgical and pathologic reports, checking whether the nodal exploration was appropriate, the location and number of mediastinal nodes and hilar/intrapulmonary nodes that were resected, and whether resection was complete.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
.
Source: OncoImmunology - Category: Cancer & Oncology Authors: Source Type: research
Opinion statementIsolation and analysis of circulating tumor DNA (ctDNA) have emerged as an effective and promising tool for genomic profiling in non-small cell lung cancer. Analysis of ctDNA can be particularly useful in situations where tissue biopsy is not safely obtainable due to poor physical condition or inaccessible tumor biopsy location. In addition to identifying oncogenic driver mutations which can be treated with targetable therapy in the treatment na ïve advanced non-small cell lung cancer (NSCLC) setting, ctDNA is being utilized in novel ways including monitoring during an advanced NSCLC patient’s t...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   NSCLC Interventions:   Drug: Kanglaite Injection+Chemotherapy;   Drug: Chemotherapy Sponsors:   Jie Li;   Ministry of Science and Technology of the People´s Republic of China;   Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
FRIDAY, June 14, 2019 -- Cardiac radiation dose exposure is a modifiable cardiac risk factor for major adverse cardiac events (MACE) and all-cause mortality (ACM) in patients with non-small cell lung cancer (NSCLC), according to a study published in...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Health | Hematology | Lung Cancer | Non-Small Cell Lung Cancer